Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points news­room is con­tin­u­ing to grow! Rey­nald Cas­tañe­da joined us this week from Lon­don — he will lead two oth­er UK col­leagues, Ay­isha Shar­ma and An­na Brown, in beef­ing up our ear­ly morn­ing re­port­ing. On the US side, Ly­dia Ram­sey Pflanz­er will be spear­head­ing the ex­pan­sion of our cov­er­age in­to health tech. If you missed it, read Drew Arm­strong’s note for more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.